Showing results (151-160 of 177) with videos related to
Sort By:
Pageof 18
The Lancet. Diabetes & Endocrinology|June 7, 2016
Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort studyRichard N Clayton, Peter W Jones, Raoul C Reulen, et al.Biochemical and Biophysical Research Communications|April 28, 2004
Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1Jillian Cornish, Andrew Grey, Karen E Callon, et al.Archives of Internal Medicine|November 13, 2008
Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older menIan R Reid, Ruth Ames, Barbara Mason, et al.BMJ (Clinical Research Ed.)|January 17, 2008
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trialMark J Bolland, P Alan Barber, Robert N Doughty, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 24, 2006
Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKLCatherine Middleton-Hardie, Qing Zhu, Harry Cundy, et al.Calcified Tissue International|October 28, 2010
Imatinib mesylate does not increase bone volume in vivoSusannah O'Sullivan, Dorit Naot, Karen E Callon, et al.The New Zealand Medical Journal|September 28, 2011
Prevalent dietary supplement use in older New Zealand menCatherine J Bacon, Mark J Bolland, Ruth W Ames, et al.The New England Journal of Medicine|January 15, 2025
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of AgeMark J Bolland, Zaynah Nisa, Anna Mellar, et al.The Journal of Biological Chemistry|February 27, 2004
Characterization of GATA3 mutations in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromeM Andrew Nesbit, Michael R Bowl, Brian Harding, et al.The Journal of Clinical Endocrinology and Metabolism|March 16, 2012
Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected menMark J Bolland, Andrew Grey, Anne M Horne, et al.Pageof 18